1. Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection
- Author
-
Sian E Faustini, Alex G. Richter, Lorraine Harper, Gemma D Banham, Adam F. Cunningham, and Alexandra Godlee
- Subjects
Male ,2019-20 coronavirus outbreak ,Time Factors ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.medical_treatment ,Comorbidity ,Antibodies, Viral ,Cohort Studies ,Renal Dialysis ,Risk Factors ,Pandemic ,medicine ,Humans ,Pandemics ,Aged ,biology ,SARS-CoV-2 ,business.industry ,COVID-19 ,General Medicine ,Middle Aged ,medicine.disease ,Virology ,Research Letters ,England ,Nephrology ,Reinfection ,Spike Glycoprotein, Coronavirus ,biology.protein ,Female ,Hemodialysis ,Antibody ,business ,Cohort study - Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have a devastating effect on patients receiving hemodialysis. To what extent infection-induced antibody responses are maintained, or protective, is unknown. This study describes the evolution of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 patients on hemodialysis. During the first wave of the pandemic, 26% of patients had developed antispike SARS-CoV-2 antibodies. Fewer PCR-confirmed second-wave infections were observed in patients with pre-existing antibodies (4.2%) than those without antibodies (11.4%). This study shows that SARS-CoV-2 antibodies in patients on hemodialysis are well maintained and associate with reduced risk of subsequent SARS-CoV-2 infection.
- Published
- 2021
- Full Text
- View/download PDF